Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	DEC 01	ChemPort single article sales feature unavailable
NEWS 3	JAN 06	The retention policy for unread STNmail messages will change in 2009 for STN-Columbus and STN-Tokyo
NEWS 4	JAN 07	WPIDS, WPINDEX, and WPIX enhanced Japanese Patent Classification Data
NEWS 5	FEB 02	Simultaneous left and right truncation (SLART) added for CERAB, COMPUAB, ELCOM, and SOLIDSTATE
NEWS 6	FEB 02	GENBANK enhanced with SET PLURALS and SET SPELLING
NEWS 7	FEB 06	Patent sequence location (PSL) data added to USGENE
NEWS 8	FEB 10	COMPENDEX reloaded and enhanced
NEWS 9	FEB 11	WTEXTILES reloaded and enhanced
NEWS 10	FEB 19	New patent-examiner citations in 300,000 CA/CAplus patent records provide insights into related prior art
NEWS 11	FEB 19	Increase the precision of your patent queries -- use terms from the IPC Thesaurus, Version 2009.01
NEWS 12	FEB 23	Several formats for image display and print options discontinued in USPATFULL and USPAT2
NEWS 13	FEB 23	MEDLINE now offers more precise author group fields and 2009 MeSH terms
NEWS 14	FEB 23	TOXCENTER updates mirror those of MEDLINE - more precise author group fields and 2009 MeSH terms
NEWS 15	FEB 23	Three million new patent records blast AEROSPACE into STN patent clusters
NEWS 16	FEB 25	USGENE enhanced with patent family and legal status display data from INPADOCDB
NEWS 17	MAR 06	INPADOCDB and INPAFAMDB enhanced with new display formats
NEWS 18	MAR 11	EPFULL backfile enhanced with additional full-text applications and grants
NEWS 19	MAR 11	ESBIOBASE reloaded and enhanced
NEWS 20	MAR 20	CAS databases on STN enhanced with new super role for nanomaterial substances
NEWS 21	MAR 23	CA/CAplus enhanced with more than 250,000 patent equivalents from China
NEWS 22	MAR 30	IMSPATENTS reloaded and enhanced
NEWS 23	APR 03	CAS coverage of exemplified prophetic substances enhanced
NEWS 24	APR 07	STN is raising the limits on saved answers

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

```
 NEWS LOGIN    Welcome Banner and News Items
 NEWS IPC8     For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN customer
  agreement.  This agreement limits use to scientific research.  Use
  for software development or design, implementation of commercial
  gateways, or use of CAS and STN data in the building of commercial
  products is prohibited and may result in loss of user privileges
  and other penalties.

* * * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 10:37:52 ON 11 APR 2009

=> file medline, uspatful, dgene, embase, wpids, biosis, hcaplus, scisearch,
biotechds
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                        ENTRY    SESSION
FULL ESTIMATED COST                                      0.44       0.44

FILE 'MEDLINE' ENTERED AT 10:38:45 ON 11 APR 2009

FILE 'USPATFULL' ENTERED AT 10:38:45 ON 11 APR 2009
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'DGENE' ENTERED AT 10:38:45 ON 11 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'EMBASE' ENTERED AT 10:38:45 ON 11 APR 2009
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 10:38:45 ON 11 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 10:38:45 ON 11 APR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 10:38:45 ON 11 APR 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 10:38:45 ON 11 APR 2009
Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 10:38:45 ON 11 APR 2009
COPYRIGHT (C) 2009 THOMSON REUTERS

=> s (compliment inhibitor polypeptide)
L1            0 (COMPLIMENT INHIBITOR POLYPEPTIDE)

=>
=> s (compliment inhibitor)
L2            2 (COMPLIMENT INHIBITOR)

=> d l2 ti abs ibib tot

L2   ANSWER 1 OF 2  USPATFULL on STN
```

TI Hapten-inhibitor immunoassay

AB A specific binding assay method employing, as a labeling substance, a reversible trypsin inhibitor for the detection of a hapten. Competition between the hapten to be determined and hapten trysin inhibitor conjugate for antibody to the hapten, in the presence of enzyme, followed by addition of enzyme substrate provides an effective method for hapten analysis. The preferred trypsin inhibitor is a protein having a molecular weight range of 2,000-75,000. The preferred ratio of the hapten to the inhibitor in the conjugate is between 1:1 and 3:1.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	84:7367 USPATFULL
TITLE:	Hapten-inhibitor immunoassay
INVENTOR(S):	March, Steven C., Libertyville, IL, United States Safford, Jr., John W., Wauconda, IL, United States Magic, Susan E., Lake Bluff, IL, United States
PATENT ASSIGNEE(S):	Abbott Laboratories, North Chicago, IL, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 4430263		19840207
APPLICATION INFO.:	US 1980-114021		19800121 (6)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1978-943073, filed on 18 Sep 1978, now abandoned		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Wiseman, Thomas G.		
LEGAL REPRESENTATIVE:	McDonnell, J. J., Shelton, D. K.		
NUMBER OF CLAIMS:	2		
EXEMPLARY CLAIM:	1		
LINE COUNT:	475		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L2 ANSWER 2 OF 2 BIOSIS COPYRIGHT (c) 2009 The Thomson Corporation on STN

TI Complement inhibitor factor H binding to lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs.

AB Borrelia burgdorferi spirochetes can circumvent the vertebrate host's immune system for long periods of time. B. burgdorferi sensu stricto and B. afzelii, but not B. garinii, bind the complement inhibitor factor H to protect themselves against complement-mediated opsonophagocytosis and killing. We found that factor H binding and complement resistance are due to inducible expression of a wide repertoire of outer surface protein E (OspE) lipoproteins variably called OspE, p21, ErpA, and ErpP. Individual Borrelia strains carry multiple plasmid-encoded OspE paralogs. Together the OspE homologs were found to constitute an array of proteins that bind factor H via multiple C-terminal domains that are exposed outwards from the Borrelial surface. Charged residue substitutions in the key binding regions account for variations between OspE family members in the optimal binding pH, temperature, and ionic strength. This may help the spirochetes to adapt into various host environments. Our finding that multiple plasmid-encoded OspE proteins act as virulence factors of Borrelia can provide new tools for the prevention and treatment of borreliosis.

ACCESSION NUMBER:	2002:561037 BIOSIS
DOCUMENT NUMBER:	PREV200200561037
TITLE:	Complement inhibitor factor H binding to lyme disease spirochetes is mediated by inducible expression of multiple plasmid-encoded outer surface protein E paralogs.
AUTHOR(S):	Alitalo, Antti; Meri, Taru; Lankinen, Hilkka; Seppala,

```
                    Ilkka; Lahdenne, Pekka; Hefty, P. Scott; Akins, Darrin;
                    Meri, Seppo [Reprint author]
CORPORATE SOURCE:   Department of Bacteriology and Immunology, University of
                    Helsinki, Haartmaninkatu 3, FIN-00014, P.O. Box 21,
                    Helsinki, Finland
                    seppo.meri@helsinki.fi
SOURCE:             Journal of Immunology, (October 1, 2002) Vol. 169, No. 7,
                    pp. 3847-3853. print.
                    CODEN: JOIMA3. ISSN: 0022-1767.
DOCUMENT TYPE:      Article
LANGUAGE:           English
ENTRY DATE:         Entered STN: 30 Oct 2002
                    Last Updated on STN: 30 Oct 2002


=> d his

     (FILE 'HOME' ENTERED AT 10:37:52 ON 11 APR 2009)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, HCAPLUS,
     SCISEARCH, BIOTECHDS' ENTERED AT 10:38:45 ON 11 APR 2009
L1             0 S (COMPLIMENT INHIBITOR POLYPEPTIDE)
L2             2 S (COMPLIMENT INHIBITOR)

=> e nunn, m/au
E1             1     NUNN WM J W/AU
E2             1     NUNN YOLONDA/AU
E3             0 --> NUNN, M/AU
E4             3     NUNNA/AU
E5             3     NUNNA C/AU
E6             1     NUNNA C R/AU
E7             1     NUNNA DYUMANI/AU
E8             1     NUNNA J/AU
E9             1     NUNNA JYOTHSNA/AU
E10            5     NUNNA K/AU
E11            8     NUNNA KALYAN/AU
E12            4     NUNNA M/AU

=> s (C5 cleavage by classical and alternative)
L3             0 (C5 CLEAVAGE BY CLASSICAL AND ALTERNATIVE)

=> s  (C5 convertases)
L4          1160 (C5 CONVERTASES)

=> s (haematophagous arthropod)
L5           148 (HAEMATOPHAGOUS ARTHROPOD)

=>  s l5 and (tick)
L6            13 L5 AND (TICK)

=> s l6 and (ornithodoros moubata)
L7             3 L6 AND (ORNITHODOROS MOUBATA)

=> d l7 ti abs ibib tot

L7   ANSWER 1 OF 3  USPATFULL on STN
TI     Complement inhibitors
AB     The invention relates to complement inhibitors that inhibit both the
       classical and alternative complement pathways. In particular, the
       invention relates to complement inhibitors derived from the salivary
       glands of haematophagous arthropods that inhibit both the classical and
```

alternative complement pathways. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER:	2007:162019 USPATFULL			
TITLE:	Complement inhibitors			
INVENTOR(S):	Nunn, Miles Andrew, Reading, UNITED KINGDOM			
	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070141573	A1	20070621	
APPLICATION INFO.:	US 2004-558937	A1	20040602	(10)
	WO 2004-GB2341		20040602	
			20070129	PCT 371 date
	NUMBER	DATE		
PRIORITY INFORMATION:	GB 2003-12619	20030602		
	GB 2003-27386	20031125		
DOCUMENT TYPE:	Utility			
FILE SEGMENT:	APPLICATION			
LEGAL REPRESENTATIVE:	KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601, US			
NUMBER OF CLAIMS:	40			
EXEMPLARY CLAIM:	1			
NUMBER OF DRAWINGS:	16 Drawing Page(s)			
LINE COUNT:	1857			

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L7 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Complement inhibitors derived from salivary gland of haematophagous arthropods for ligand screening and diagnosis/treatment of complement-mediated diseases

AB The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways, i.e. inhibit cleavage of C5 by C5 convertase without affecting C3 activation. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The haematophagous arthropod is a tick such as Ornithodoros moubata, and the complement inhibitor is e.g. OmCI protein. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. The diseases include Alzheimer's disease, rheumatoid arthritis, glomerulonephritis, reperfusion injury, transplant rejection, sepsis, immune complex disorder or delayed-type hypersensitivity.

ACCESSION NUMBER:	2004:1059382 HCAPLUS
DOCUMENT NUMBER:	142:54766
TITLE:	Complement inhibitors derived from salivary gland of haematophagous arthropods for ligand screening and diagnosis/treatment of complement-mediated diseases
INVENTOR(S):	Nunn, Miles Andrew
PATENT ASSIGNEE(S):	Evolutec Limited, UK
SOURCE:	PCT Int. Appl., 63 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	1
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106369	A2	20041209	WO 2004-GB2341	20040602
WO 2004106369	A3	20050217		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2004242759	A1	20041209	AU 2004-242759	20040602
CA 2526083	A1	20041209	CA 2004-2526083	20040602
EP 1629098	A2	20060301	EP 2004-735758	20040602
EP 1629098	B1	20090401		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
BR 2004010876	A	20060704	BR 2004-10876	20040602
CN 1798841	A	20060705	CN 2004-80015178	20040602
JP 2007536894	T	20071220	JP 2006-508386	20040602
MX 2005012880	A	20060222	MX 2005-12880	20051129
US 20070141573	A1	20070621	US 2007-558937	20070129
PRIORITY APPLN. INFO.:			GB 2003-12619 A	20030602
			GB 2003-27386 A	20031125
			WO 2004-GB2341 W	20040602
REFERENCE COUNT: 1		THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L7 ANSWER 3 OF 3 SCISEARCH COPYRIGHT (c) 2009 The Thomson Corporation on STN

TI Displaced tick-parasite interactions at the host interface

AB Reciprocal interactions of parasites transmitted by blood-sucking arthropod vectors have been studied primarily at the parasite-host and parasite-vector interface. The third component of this parasite triangle, the vector-host interface, has been largely ignored. Now there is growing realization that reciprocal interactions between arthropod vectors and their vertebrate hosts play a pivotal role in the survival of arthropod-borne viruses, bacteria, and protozoa. The vector-host interface is the site where the haematophagous arthropod feeds. To obtain a blood meal, the vector must overcome the host's inflammatory, haemostatic, and immune responses. This problem is greatest for ixodid ticks which may imbibe as much as 15 ml blood whilst continuously attached to their host for 10 days or more. To feed successfully, the interface between tick and host becomes a battle between the host's mechanisms for combating the tick and the tick's armoury of bioactive proteins and other chemicals which it secretes, via saliva, into the feeding lesion formed in the host's skin. Parasites entering this battlefield encounter a privileged site in their vertebrate host that has been profoundly modified by the pharmacological activities of their vector's saliva. For example, ticks suppress natural killer cells and interferons, both of which have potent antiviral activities. Not surprisingly, vector-borne parasites exploit the immunomodulated feeding site to promote their transmission and infection. Certain tick-borne viruses are so successful at this that they are transmitted from one infected tick, through the vertebrate host to a co-feeding uninfected tick, without a detectable viraemia (virus circulating in the host's blood), and with no

```
     untoward effect on the host.  When such viruses do have an adverse effect
     on the host, they may impede their vectors' feeding.  Thus important
     interactions between ticks and tick-borne parasites are
     displaced to the interface with their vertebrate host - the skin site of
     blood-feeding and infection.
ACCESSION NUMBER:    1998:560384  SCISEARCH
THE GENUINE ARTICLE: 100CU
TITLE:               Displaced tick-parasite interactions at the host
                     interface
AUTHOR:              Nuttall P A (Reprint)
CORPORATE SOURCE:    NERC, Inst Virol & Environm Microbiol, Mansfield Rd,
                     Oxford OX1 3SR, England (Reprint)
AUTHOR:              Nuttall P A (Reprint)
CORPORATE SOURCE:    NERC, Inst Virol & Environm Microbiol, Oxford OX1 3SR,
                     England
COUNTRY OF AUTHOR:   England
SOURCE:              PARASITOLOGY, (1998) Vol. 116, Supp. [S], pp. S65-S72.
                     ISSN: 0031-1820.
PUBLISHER:           CAMBRIDGE UNIV PRESS, 40 WEST 20TH ST, NEW YORK, NY
                     10011-4221 USA.
DOCUMENT TYPE:       Article; Journal
LANGUAGE:            English
REFERENCE COUNT:     48
ENTRY DATE:          Entered STN: 1998
                     Last Updated on STN: 1998
                    *ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS*


=> d his

     (FILE 'HOME' ENTERED AT 10:37:52 ON 11 APR 2009)

     FILE 'MEDLINE, USPATFULL, DGENE, EMBASE, WPIDS, BIOSIS, HCAPLUS,
     SCISEARCH, BIOTECHDS' ENTERED AT 10:38:45 ON 11 APR 2009
L1             0 S (COMPLIMENT INHIBITOR POLYPEPTIDE)
L2             2 S (COMPLIMENT INHIBITOR)
               E NUNN, M/AU
L3             0 S (C5 CLEAVAGE BY CLASSICAL AND ALTERNATIVE)
L4          1160 S  (C5 CONVERTASES)
L5           148 S (HAEMATOPHAGOUS ARTHROPOD)
L6            13 S L5 AND (TICK)
L7             3 S L6 AND (ORNITHODOROS MOUBATA)

=> s l5 and (complement inhibitor)
L8             2 L5 AND (COMPLEMENT INHIBITOR)

=> d l8 ti abs ibib tot

L8   ANSWER 1 OF 2  USPATFULL on STN
TI     Complement inhibitors
AB     The invention relates to complement inhibitors that inhibit both the
       classical and alternative complement pathways. In particular, the
       invention relates to complement inhibitors derived from the salivary
       glands of haematophagous arthropods that inhibit both the classical and
       alternative complement pathways. The invention also relates to the use
       of such complement inhibitors in the treatment and prevention of
       diseases.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
ACCESSION NUMBER:       2007:162019  USPATFULL
TITLE:                  Complement inhibitors
```

INVENTOR(S): Nunn, Miles Andrew, Reading, UNITED KINGDOM

	NUMBER	KIND	DATE	
PATENT INFORMATION:	US 20070141573	A1	20070621	
APPLICATION INFO.:	US 2004-558937	A1	20040602	(10)
	WO 2004-GB2341		20040602	
			20070129	PCT 371 date

	NUMBER	DATE
PRIORITY INFORMATION:	GB 2003-12619	20030602
	GB 2003-27386	20031125

DOCUMENT TYPE: Utility
FILE SEGMENT: APPLICATION
LEGAL REPRESENTATIVE: KLAUBER & JACKSON, 411 HACKENSACK AVENUE, HACKENSACK, NJ, 07601, US
NUMBER OF CLAIMS: 40
EXEMPLARY CLAIM: 1
NUMBER OF DRAWINGS: 16 Drawing Page(s)
LINE COUNT: 1857
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2009 ACS on STN
TI Complement inhibitors derived from salivary gland of haematophagous arthropods for ligand screening and diagnosis/treatment of complement-mediated diseases
AB The invention relates to complement inhibitors that inhibit both the classical and alternative complement pathways, i.e. inhibit cleavage of C5 by C5 convertase without affecting C3 activation. In particular, the invention relates to complement inhibitors derived from the salivary glands of haematophagous arthropods that inhibit both the classical and alternative complement pathways. The haematophagous arthropod is a tick such as Ornithodoros moubata, and the complement inhibitor is e.g. OmCI protein. The invention also relates to the use of such complement inhibitors in the treatment and prevention of diseases. The diseases include Alzheimer's disease, rheumatoid arthritis, glomerulonephritis, reperfusion injury, transplant rejection, sepsis, immune complex disorder or delayed-type hypersensitivity.

ACCESSION NUMBER: 2004:1059382 HCAPLUS
DOCUMENT NUMBER: 142:54766
TITLE: Complement inhibitors derived from salivary gland of haematophagous arthropods for ligand screening and diagnosis/treatment of complement-mediated diseases
INVENTOR(S): Nunn, Miles Andrew
PATENT ASSIGNEE(S): Evolutec Limited, UK
SOURCE: PCT Int. Appl., 63 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004106369	A2	20041209	WO 2004-GB2341	20040602
WO 2004106369	A3	20050217		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,

```
            LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
            NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
            TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
        RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
            AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
            EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
            SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
            SN, TD, TG
    AU 2004242759          A1    20041209    AU 2004-242759          20040602
    CA 2526083             A1    20041209    CA 2004-2526083         20040602
    EP 1629098             A2    20060301    EP 2004-735758          20040602
    EP 1629098             B1    20090401
        R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
            IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
    BR 2004010876          A     20060704    BR 2004-10876           20040602
    CN 1798841             A     20060705    CN 2004-80015178        20040602
    JP 2007536894          T     20071220    JP 2006-508386          20040602
    MX 2005012880          A     20060222    MX 2005-12880           20051129
    US 20070141573         A1    20070621    US 2007-558937          20070129
PRIORITY APPLN. INFO.:                        GB 2003-12619       A   20030602
                                              GB 2003-27386       A   20031125
                                              WO 2004-GB2341      W   20040602
REFERENCE COUNT:          1     THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS
                                RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
```